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Malaria elimination will be possible only with serious attempts to address asymptomatic infection and chronic
infection by both Plasmodium falciparum and Plasmodium vivax. Currently available drugs that can completely clear
a human of P. vivax (known as “radical cure”), and that can reduce transmission of malaria parasites, are those in the
8-aminoquinoline drug family, such as primaquine. Unfortunately, people with glucose-6-phosphate dehydrogenase
(G6PD) deficiency risk having severe adverse reactions if exposed to these drugs at certain doses. G6PD deficiency is
the most common human enzyme defect, affecting approximately 400 million people worldwide.
Scaling up radical cure regimens will require testing for G6PD deficiency, at two levels: 1) the individual level to ensure
safe case management, and 2) the population level to understand the risk in the local population to guide Plasmodium
vivax treatment policy. Several technical and operational knowledge gaps must be addressed to expand access
to G6PD deficiency testing and to ensure that a patient’s G6PD status is known before deciding to administer an
8-aminoquinoline-based drug.
In this report from a stakeholder meeting held in Thailand on October 4 and 5, 2012, G6PD testing in support of radical
cure is discussed in detail. The focus is on challenges to the development and evaluation of G6PD diagnostic tests, and
on challenges related to the operational aspects of implementing G6PD testing in support of radical cure. The report also
describes recommendations for evaluation of diagnostic tests for G6PD deficiency in support of radical cure.Goals of the G6PD workshop
In October 2012, a workshop in Bangkok, Thailand,
brought together researchers, diagnostic test developers,
drug developers, National Malaria Control Programme
(NMCP) representatives, development partners and donors
to discuss priority issues related to malaria treatment
[1]. The workshop built upon two previous meetings: a
March 2012 meeting in London on the rationale for
short-course primaquine in Africa to interrupt malaria
transmission [2] and a May 2012 workshop on glucose-
6-phosphate dehydrogenase (G6PD) deficiency that was
held in South Korea as part of the Asia Pacific Malaria* Correspondence: gdomingo@path.org
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meeting [3,4]. The Bangkok workshop provided a forum
for discussing the knowledge gaps, barriers, and research
questions that must be addressed to support broader
availability, adoption, and access to G6PD testing in sup-
port of radical cure of Plasmodium vivax.
The goals of the Bangkok workshop were to:
1. Identify technical research priorities to support
development of appropriate G6PD testing
technologies and strategies in support of P. vivax
radical cure.
2. Define use case scenarios or malaria treatment-seeking
behaviours that a G6PD test or test result
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implementation of appropriate G6PD testing
technologies and strategies.
Primaquine can be used at low doses as a malaria
gametocytocidal to block the transmission of the parasite
to the mosquito, or it can be used at higher doses in
longer regimens for radical cure of P. vivax infection. The
workshop focused on the use of G6PD testing in support
of radical cure. The agenda and selected presentations
are available online [1].
Background and context
G6PD deficiency is the most common human enzyme
defect, affecting more than 400 million people worldwide
[5]. Several recent reviews have explored the relationship
between malaria and G6PD deficiency [4,6-8]. The meet-
ing focused on topics relevant to developing and evaluat-
ing in vitro diagnostic tests for G6PD activity.
Glucose-6-phosphate dehydrogenase
G6PD is a critical housekeeping enzyme in red blood
cells that supports protective systems against oxidative
challenge by producing the reduced form of nicotinamide
adenine dinucleotide phosphate (NADPH). The gene
for the G6PD enzyme is spread over 18.5 Kb and 13
exons on the X chromosome and encodes for a 59 KDa
polypeptide. The enzyme is active as a dimer or dimer
of dimers configuration. G6PD deficiency is manifested
in people with reduced levels of intra-erythrocyte G6PD
activity arising typically from mutations in the G6PD gene
that impact the stability of the enzyme.
Results from several studies suggest that G6PD deficiency
may confer some protection not only against severe malaria
but also against non-severe disease [9-11]. Indeed, G6PD
deficiency prevalence overlaps significantly with current
and historical malaria endemicity [12]. Within these
populations, the protection conferred by G6PD deficiency
may result in a reduced prevalence of G6PD deficiency
among malarial patients as compared to the general
population [9-11].
Definition of G6PD activity
One International Unit (U) is the amount of G6PD activity
that will convert 1 micromole of NADP + per minute
under predetermined substrate and reaction conditions
[13]. Activity may be expressed in either a standard
number of cells (U/1012 red blood cells) or amount of
haemoglobin (U/g Hb). G6PD activity is typically deter-
mined by measuring G6PD activity in lysate from a
whole blood specimen or a red blood cell preparation from
a specimen. G6PD deficiency is defined as a less-than-
normal level of G6PD enzyme activity in a blood specimen.Almost 400 allelic variants in the G6PD gene have
been recorded [8,14,15]. The variants known to result
in G6PD deficiency tend to affect the stability of the
enzyme rather than the catalytic activity of the enzyme
[7,8,14,15]. G6PD variants are categorized based on the
severity of the G6PD deficiency they cause. Class 1 variants
cause congenital non-spherocytic haemolytic anaemia.
Class 2 variants cause severe enzyme deficiency (less than
10% of normal). Class 3 variants cause moderate to
mild enzyme deficiency (10% to 60% of normal). Class
4 variants cause very mild or no enzyme deficiency
(60% to 100% of normal) [13,16]. How these activity
ranges relate to safety of exposure to 8-aminoquinolines
is not very clear, nor is the definition of normal, as dis-
cussed below.
8-aminoquinolines, malaria, and G6PD deficiency
Primaquine, an 8-aminoquinoline-based drug, is the only
available drug recommended by the World Health Or-
ganization (WHO) for radical cure of P. vivax infection.
The next most advanced product for radical cure is tafeno-
quine, which recently completed phase 2 clinical trials.
As a radical cure, primaquine is currently used either in
a 7 or 14 day regimen in a doses ranging from 0.25-0.5
mg/kg. For patients with mild to moderate variants of
G6PD deficiency, a once-per-week, single 0.75 mg/kg dose
of primaquine over eight weeks is recommended, although
careful monitoring for hemolysis is also recommended.
Unfortunately, none of these regimens is operationally
easy to implement. In Brazil and Peru, this has been
partially addressed by using a higher-dose, shorter-length
primaquine regimen. Tafenoquine as a single-dose radical
cure therapy would represent a significant advance in
P. vivax therapy. However, a major barrier to widescale
adoption of both of these drugs is toxicity in people with
G6PD deficiency. While all people exposed to primaquine
experience some drop in haemoglobin concentrations
[17], people with G6PD deficiency are more likely to
experience severe haemolysis, leading to severe haemolytic
anaemia and, potentially, death. Despite the availability of
primaquine since the 1950s, safety data are scarce.
WHO, confronted with emerging resistance to artemisi-
nin and renewed political will to eliminate malaria in many
regions of the world, recently released recommendations
to administer low doses of primaquine to all patients
presenting with falciparum malaria in those settings
[18,19]. Based on available data, the new recommended
doses are suggested to be low enough to be safe even
for G6PD-deficient patients but high enough to have a
gametocytocidal effect and block transmission [19,20].
However, before these recommendations can be imple-
mented, primaquine will need to be registered in many
countries for this use. Uganda and other countries are
conducting studies to better understand local prevalence
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these low doses [2,21].
User requirements and target product profile for G6PD tests
The possible role of G6PD tests within the context of
using primaquine for blocking transmission has been
discussed elsewhere [2,18,19]. The Bangkok workshop
focused on diagnostic tests for G6PD deficiency in P. vivax
case management. One breakout session was dedicated to
identifying how a patient typically presents with P. vivax
infection, how the patient is managed in this scenario, and
what type of diagnostic test would be required to support
case management. Scenarios were created for Cambodia,
India, Myanmar, and Thailand. At least one national
malaria control programme representative participated,
along with researchers with experience in each country.
The different country groups were asked to select a target
patient profile, regardless of whether this type of patient
carried the highest burden of disease.Table 1 Product features of a point-of-care G6PD test in supp
Features Ideal Acceptab
Test output Binary, deficient/normal Quantitat
User Village health workers, mobile
malaria workers
District ho
worker
Platform Point-of-care similar to a
malaria rapid diagnostic test
A disposa
portable,
sensitivity
human ey
Specimen type Capillary blood Capillary
Stability
requirements
2 years at 37°C 1 year at
Packaging Maximum 25 tests per kit Maximum
Operational
temperature range
25-40°C 25-40°C
Operational
humidity range
40-90% 40-90%
Time to result <10 minutes <30minu
Read window >1 hour 10 minut
Sensitivity Detects all patients (100%) with G6PD
activity less than a predetermined cut-off,
at or less than which it is unsafe to prescribe
a particular dosage of an 8-aminoquinoline
>95% for
a defined
Specificity >95% >70%
Price Similar to or less than a malaria
rapid diagnostic test
Similar to
malaria raIn all four settings, it was determined that the target
patient would benefit most from a point-of-care G6PD
test. There was robust debate over who would use the
test and exactly how far into the periphery of the health
system the test should go, depending on how complex
the treatment algorithm would be. For many cases,
based on the fact that many users would have access to
a mobile phone and, therefore, some access to electric
power, participants felt that some type of automated
reader, while not ideal, may be acceptable. While a reader
may restrict some access, it can also confer benefits,
such as remote monitoring, and it could possibly support
some means of recordkeeping [22]. Part of the Bangkok
discussion revolved around how often a G6PD test would
have to be performed for each individual, and a discussion
arose regarding the challenges of record keeping, espe-
cially with migrant populations.
Based on this discussion, workshop participants created
a generic target product profile (Table 1) [4].ort of radical cure
le Comments
ive Presumes a consensus definition
of normal that aligns with drug safety
spital, laboratory This will be defined by national
malaria control programmes
ble device coupled to a
battery-operated device;
significantly better than
e
A reader would be acceptable if it significantly
improves operational performance
blood Tests must be evaluated for performance
with this specimen type
37°C Expect low throughput at clinic level,
so requires small quantities per package
or long shelf life
25 tests per kit
G6PD enzyme activity is highly temperature
dependent (see Figure 2)
None.
tes Availability of the test result should be
aligned with malaria diagnosis and
treatment work flow
es Ideally, the test result can be read at any
time point after the initial time to result
patients at or less than
cut-off G6PD activity
For primaquine, where the fluorescent spot
test has been accepted as the standard of
care, a 30-40% normal G6PD activity cut-off
should be used; for new drugs such as
tafenoquine, the cut-off is likely to be higher
It is preferable to have some patients with
normal G6PD activity levels classified as
deficient as determined by the Receiver
Operating Curve of a diagnostic test
or less than a
pid diagnostic test
G6PD test represents an additional cost over
that of malaria diagnosis and treatment
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G6PD activity tests
A survey of products and reagents available for G6PD
deficiency testing shows a surprisingly large number of
products in the market (more than 20). Available tests
determine the G6PD phenotype and overall G6PD activity
in a blood specimen, either by direct measurement or
through dyes. The outputs can be quantitative, semi-
quantitative, or qualitative depending on the platform
and assay. Different types of G6PD phenotype assays
have recently been reviewed [4,6,23,24].
When workshop attendees were asked which G6PD
tests they use, more than 15 products were mentioned,
spanning at least three assay platforms. Perhaps the
most consolidated G6PD products are those used for
newborn screening, which often have high-complexity
and sometimes high-throughput platforms [25]. These
tests are used in Southeast Asia in national newborn
screening due to the high G6PD deficiency prevalence in
the region and the risk for infants to develop severe
hyperbilirubinaemia, acute bilirubin encephalopathy, and
kernicterus [26,27].
Quantitative tests for G6PD activity are considered the
gold standard. Yet the predominant standard of care for
G6PD deficiency screening is a qualitative test, the fluor-
escent spot test, for which there are several commercial
kits as well as homebrew assays (assays assembled in
the testing laboratory). Beyond those, the wide range of
products in the market offer different levels of com-
plexity, usability, and performance. Some of these tests
have been developed on platforms more suitable for use
within the context of malaria case management [28-33].
Overall, with few exceptions [34], there is a paucity of
published data that compare G6PD deficiency determin-
ation across platforms, and most products on the market
have not been evaluated independently.G6PD genotype tests
G6PD genotype tests characterize the genetic contribution
to the G6PD phenotype in a patient. There are several
levels at which these tests can be performed, with different
degrees of accuracy or resolution. Gel electrophoresis or
cytochemical staining can indirectly determine zygosity
in females based on whether two G6PD proteins with
distinct electrophoretic characteristics or two red cell
populations with distinct G6PD activity profiles are
observed respectively [35-37]. These are predominantly
laboratory-based or homebrew assays. More typically,
genotyping is performed through polymerase chain reac-
tion (PCR)-based single nucleotide polymorphism (SNP)
analysis, and some commercial primer sets are available
to determine the genotype through multiplexed PCR.
Because not all SNPs can be multiplexed into a singlePCR reaction, different panels have been developed based
on population prevalence. This genotyping approach is
limited to identifying known genotypes and results in
severely biased genotype data. Consequently, when
both genotyping and phenotyping have been performed
on the same patients, the correlation has been mixed
[9,38,39]. This is possibly due to different populations
experiencing different degrees of polymorphism in this
gene and to the severity in G6PD deficiency conferred
by the prevalent genotype in a given population.
Sequencing provides the most deterministic G6PD
gene characterization, but the G6PD gene—with its 12
introns and 13 exons spanning 18.5 Kb base pairs—is an
awkward gene to sequence economically. Given the new
sequencing technologies now available, investments should
be made in developing multiplexed sequencing assays
that look at a range of haemoglobinopathies. Research
ethics and consent implications for this type of multi-
plexed sequencing assay need to be openly investigated
and discussed.
Technical knowledge gaps
To develop G6PD tests that will inform patient manage-
ment with 8-aminoquinolines, many questions remain to
be answered, both in terms of the G6PD assay itself and
the clinical context. Most of these questions revolve around
two fundamental issues: (1) defining normal G6PD activity,
and (2) defining a G6PD activity cut-off greater than which
it is safe to administer a drug at a given.Defining normal G6PD activity
For the purpose of evaluating diagnostic tests for G6PD
deficiency a standard approach for defining an absolute
value for normal G6PD activity in a population is required.
Ambiguity in how this value is calculated presents practical
difficulties in evaluating the performance of G6PD tests,
and particularly that of qualitative tests. For qualitative
tests, performance will depend on the boundary, or the
cut-off point, between normal and deficiency. Typically,
G6PD deficiency has been defined as a percentage of
normal G6PD activity. In practice, there are almost as
many definitions of normal activity as there are publica-
tions for evaluating G6PD diagnostic tests [30-33,40,41].
Defining the boundary between normal G6PD activity
and G6PD deficiency
Further complicating the issue, there is a paucity of data
to correlate definitions for different degrees of G6PD
deficiency with risk after exposure to an 8-aminoquinoline
challenge [6,42]. This remains a major knowledge gap in
understanding G6PD deficiency and the risk of exposure
to primaquine and tafenoquine. While it is known that
G6PD genotypes differentially impact the response to
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the known G6PD deficiency traits [43,44]. Additionally,
acceptable G6PD activity levels for primaquine adminis-
tration have been defined by the most predominantly used
G6PD assay—the fluorescent spot test. This test, by nature
of its assay conditions, defines “deficient” at approximately
10% to 30% of normal G6PD activity. As a result, people
with severe G6PD deficiency are predominantly excluded
from primaquine treatment, whereas most people with
mild G6PD activity and most heterozygous women are
treated with primaquine. Anecdotally, “this works,” but
there are no supportive, published data.
If the goal is to expose only patients with normal
G6PD activity to 8-aminoquinolines, then the cut-off
G6PD activity level would have to be in range of 60% to
70% of normal values, as per the WHO classification. This
would also exclude a significant portion of heterozygous
women, at least those in whom there are a significant
proportion of G6PD-deficient red blood cells.
These two arbitrary definitions or cut-offs have an
immense impact on performance requirements for a G6PD
test. This is a consequence of the distribution of G6PD
activities across a population (Figure 1). Typically, G6PD
activity in a population is bimodal, with a minor group
of individuals clustered around 10% or less G6PD activity
and most clustered in the 60% to 150% range. The 10%
to 30% G6PD activity cut-off considered acceptable for
primaquine is essentially defined by the fluorescent spot
test, a qualitative test for G6PD activity. Thus, developing
additional qualitative G6PD tests with similar performance
is presumably feasible, though there is a need for im-
proved understanding of the impact of different genotypes
on the performance of such qualitative tests against a
quantitative test.
By contrast, developing a qualitative G6PD test that
accurately excludes patients with less than 60% or 70%0
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Figure 1 Histogram of G6PD activity for a population described
in Table 3; 10%, 20%, 30%, and 60% of the adjusted normal
G6PD activity for this population are indicated on the graph.G6PD activity is likely to be extremely challenging,
given the noise-to-signal levels that are likely to exist at
this level of activity. A test with discriminatory capabilities
in the 60% to 70% cut-off range is likely to require an
underlying quantitative or semi-quantitative platform.
Unfortunately, published G6PD test evaluations use
inconsistent definitions of normal G6PD activity and also
define test sensitivity and specificity based on different
cut-off points or degrees of G6PD deficiency. Thus, it is
challenging to understand what a qualitative G6PD test
defines as normal or deficient and to compare perform-
ance claims between publications. Consistent standards
for evaluating G6PD tests are sorely needed.
Factors affecting G6PD test performance
Several factors can influence the performance of a G6PD
test and its ability to correctly classify a patient as either
normal or deficient, starting with the cut-off definition as
previously described. These include biological conditions
such as concomitant haemoglobinopathies, recent haemo-
lytic events that leave a patient with a relatively high
proportion of young cells with high G6PD activity that
can produce a false normal result, and high leukocyte
counts that also lead to a false normal G6PD result. For
some of these factors—including a recent malaria infection
or other pathological events—it may be possible to predict
their effects on a G6PD activity-based assay, but it is still
difficult to know how they may affect the risk of an adverse
reaction to 8-aminoquinoline exposure. Understanding
the impact of haemoglobinopathies and recent haemolytic
events on a patient’s response to 8-aminoquinolines and
the test performance are critical research questions [4].
Because they are enzyme activity tests, the G6PD assays
are particularly sensitive to specimen handling and re-
action conditions. Specimen integrity is highly sensitive
to handling and storage conditions. Acceptable specimen
storage conditions for whole blood is up to 14 days at 4°C
and for dried blood spots up to 10 days at 4°C or 48–72
hours at room temperature [28,31,45]. Substrate concen-
trations and fluctuations in assay temperature influence
the enzyme turnover rate. A change of approximately 1
degree in temperature produces a change of 6% in enzyme
activity (Figure 2A) [13]. The effect of temperature on
G6PD activity values can be accounted for quite effectively
by temperature correction factors (Figure 2B). However, in
the case of qualitative tests, this may lead to misclassifying
deficient specimens as normal if a test is used outside the
validated working temperature range (Figure 2C). The
combined impact of compromises in specimen collection
and operational reaction conditions on the performance of
the test in typical malaria treatment settings may result in
a wider gap between operational performance of a G6PD
test and analytical performance of the test determined
under controlled laboratory conditions.
BA
C
Figure 2 Impact of temperature on G6PD activity-based tests. A. Impact of temperature on quantitative determinations of G6PD activity for
five normal and four deficient G6PD samples. B. Normalization of G6PD activity to 30°C through application of the temperature correction factor
(Table 2) to values in A. C. Impact of temperature on outputs from a qualitative G6PD test. The deficient sample test result at high temperature
looks similar to that of a normal sample at low temperature. Note: the temperature range used for Figure 2C is outside the recommended
temperature range in the product insert.
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deficiency affect the stability of the enzyme and specif-
ically the dimer interface [15,46]. Consequently, the
dilution factor to which the specimen is subjected in
the final assay is also likely to affect the test result and
this effect is potentially variant specific (Table 2).
Given that the fluorescent spot test is the current
standard of care, it will be important to compare the
performance of the fluorescent spot test against a
quantitative test in different geographical settings to
understand this relationship.
In the case of females with heterozygous G6PD alleles,
while many display a phenotype of intermediate or mild
G6PD deficiency, it is clear from available data that het-
erozygous women cannot be accurately identified through
G6PD enzyme activity assays.Table 2 Factor by which blood is diluted in the final G6PD ac
diagnostic platforms
Trinity biotech G-6-
PDH quantitative test
R&D diagnostics Ltd
quantitative test
Trinit
fluore
Initial specimen
volume
10 ul 5 μl 10 μl
Dilution factor 301 80 21
G-6-PDH: glucose-6-phosphate dehydrogenase.Proposed principles for evaluating diagnostic tests
G6PD tests play a critical safety role in strategies involving
radical cure of P. vivax malaria and there is demand for
evaluation of the tests. Defining pragmatic guidelines
for the evaluation of G6PD tests will be critical to allow
comparison of findings between evaluation studies. Below,
one approach which would allow meta-analysis of data
across sites is suggested. A quantitative test for the gold
standard is recommended, but it is also recognized that
it is not trivial to implement a G6PD quantitative assay
in many field sites.
Study population description
Minimal study population characteristics that need to be
assessed for any field evaluation include the proportion
of G6PD-deficient cases in the study population, meantivity assay as performed on different G6PD deficiency
y biotech G-6-PDH
scent spot test
Alere BinaxNOWW
Malaria test
Access Bio CareStart™ G6PD
deficiency screening test
10 μl 3 μl
8 41
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the adjusted male median activity (see below and Table 3).
Mean and median values of G6PD activity need to be
stratified by gender and adjusted for ambient temperature
and the proportion of G6PD-deficient study participants
(see below).
If purposive patient recruitment results in inclusion of
more G6PD-deficient patients than the local prevalence,
mean and median G6PD activity levels also should be
provided for the normal males in the study.
Definitions
The definitions provided below are for performance
comparison of a qualitative G6PD test to a quantitative
G6PD test.
Male median
To minimize the impact of heterozygosity on the defin-
ition of G6PD activity, researchers should use the median
value of G6PD activity for the entire male population
in the study. If purposive or biased recruitment were
used for an evaluation, the median G6PD value of the
G6PD-normal male recruited for the study should be
used as the definition of normal. Otherwise, an adjusted
male median calculated as described below should
be used.
Adjusted median (100% G6PD activity)
To account for variability in prevalence of G6PD defi-
ciency in a given study population, an adjusted median
value is calculated for which males with severe G6PD
deficiency (activity less than 10% normal) have been
excluded. This is accomplished by:
1. Exclusion of all males with G6PD activity equal to or
less than 10% of the male median.
2. Determination of a new median G6PD activity. This
is the “adjusted median,” which can be used as the
100% G6PD activity value from which cut-off levels
are defined.Table 3 Proposed reference values to describe the G6PD
activity profile for a study population
Reference values Total Female Male Adjusted male
Number of cases 500 282 218 203
Mean (95% CI) U/g Hb 10.23 10.38 10.03 10.72
Standard deviation 2.28 2.10 2.52 1.97
Median (95% CI) U/g Hb 10.33 10.31 10.34 10.70
Range 0-32.25 0.38-32.25 0-24.32 1.50-24.32
CI: confidence interval; Hb: haemoglobin; U: International Unit.
The table is populated with an example data set randomly selected from a
true set of quantitative G6PD test results for a population (data kindly
provided by Ari Satyagraha).Cut-off
The percentage of adjusted median at or less than which
a patient is classified as positive (G6PD deficient). Samples
with G6PD activity greater than the cut-off are considered
negative.
True positive (TP)
A sample correctly classified by the diagnostic test under
evaluation as having G6PD activity at or less than the
cut-off.
False positive (FP)
A sample incorrectly classified by the diagnostic test
under evaluation as having G6PD activity at or less than
the cut-off.
True negative (TN)
A sample correctly classified by the diagnostic test under
evaluation as having G6PD activity greater than the cut-off.
False negative (FN)
A sample incorrectly classified by the diagnostic test
under evaluation as having G6PD activity greater than
the cut-off.
Range of patients that should be excluded from
treatment with 8-aminoquinolines
All patients with G6PD activity less than or equal to the
cut-off as determined by the gold standard test (TP + FN).
Range of patients with levels of G6PD activity safe to
receive treatment with 8-aminoquinolines
All patients with G6PD activity greater than the cut-off
(TN + FP).
Sensitivity
Probability that the test will detect a person with G6PD
deficiency.
Sensitivity ¼ TP
TP þ FN
Specificity
Probability that the test will detect a person with G6PD-
normal activity.
Specificity ¼ TN
TN þ FP
Positive predictive value
Probability that the patient is G6PD deficient when the
diagnostic test under evaluation yields a positive result.
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TP þ FP
Negative predictive value
Probability that the patient has normal G6PD activity
when the diagnostic test yields a negative result.
Negative predictive value ¼ TN
TN þ FN
Gold standard testing
An established quantitative G6PD test should be imple-
mented as the gold standard test for which 100% G6PD
activity and the cut-offs are defined. The quality of the
quantitative test should be controlled either through
commercially available artificial controls or through
samples with known G6PD activity levels. Ideally, this
is performed under strict temperature control using
venous blood (acid-citrate-dextrose or EDTA anticoagu-
lant). If strict temperature control cannot be applied,
the temperatures at which the assays were performed
should be recorded and then standardized to G6PD
activity at 30°C according to temperature correction
factors. Some product inserts, such as those for the
Trinity Biotech. quantitative test, provide temperature
correction factors (Table 4).
Sample size calculations for diagnostic test evaluation
The sample size for evaluations of G6PD tests is driven
by the expected performance of the diagnostic test
against the predicate gold standard, the local G6PD
deficiency prevalence, and the desired accuracy for
resulting sensitivity and specificity claims (width of 95%Table 4 Temperature correction factor as provided in
the Trinity quantitative spectrophotometric assay
product insert
Cuvette
temperature (°C)
Temperature
correction factor
Cuvette
temperature (°C)
Temperature
correction factor
20 1.90 30 1.00
21 1.76 31 0.94
22 1.66 32 0.89
23 1.55 33 0.83
24 1.46 34 0.78
25 1.37 35 0.74
26 1.28 36 0.70
27 1.20 37 0.66
28 1.13 38 0.62
29 1.06 39 0.58confidence intervals around estimates of sensitivity and
specificity). Given the relatively low G6PD deficiency
prevalence in most populations worldwide, the sample
size is primarily driven by the prevalence and desired
accuracy for the evaluation results. Table 5 shows sample
calculations for a set of expected test sensitivities over
two accuracy constraints and for three G6PD deficiency
prevalence rates. In the absence of an appropriate sample
size, the statistical power of the study is compromised
and the implied uncertainty of the study must be
clearly explained.
G6PD test performance criteria
In the absence of a more complete understanding of the
relationship between risk of haemolysis and level of
G6PD deficiency, as well as local G6PD reference values,
it is impossible to define a clear normal/deficient G6PD
activity cut-off that is consistent and clinically relevant as
pertaining to safety and treatment with an 8-aminoquino-
line. As a consequence, test performance criteria should
be provided for a range of G6PD activity. Percentage of
median activity is proposed in order to account for
inter-assay and inter-laboratory variability in absolute
G6PD activity values. The minimum proposed degrees
of deficiency are based on WHO classifications and
commonly used ranges: 10%, 20%, 30%, and 60% of the
normal male or adjusted median G6PD activity. Absolute
cut-off values (in U/g Hb) and sensitivity, specificity,
positive predictive value, and negative predictive value
should be determined for this range of degrees of G6PD
deficiency. Example performance data for the evaluation
of a putative G6PD test are described in Tables 3 and 6;
the cut-offs are shown in Figure 1.
Regulatory considerations for G6PD testing
The first step toward regulating the quality of G6PD
tests will be to define evaluation standards for this class
of diagnostic tests. In many countries where G6PD
tests are needed to support P. vivax case management,
regulatory mechanisms for diagnostic tests are absent,
weak, or in transition. In the absence of national guide-
lines, some countries default to CE mark and US Food
and Drug Administration (FDA) approval. Currently,
the BinaxNOWW G6PD test marketed in the United States
has obtained FDA approval under 510(k) clearance. Most
G6PD tests on the market have at best obtained only CE
mark approval.
There is a concern that without clear guidelines for
G6PD testing performance criteria, point-of-care G6PD
testing will follow a similar route as the malaria rapid
diagnostic tests (RDTs), albeit to a smaller scale, wherein
a large number of products with varying degrees of quality
control and performance entered the market. Variability in
RDT quality produced distrust of the product generally,
Table 5 Sample size calculations for evaluation of G6PD diagnostic tests for radical cure
Expected
sensitivity
Desired
width of CI
Confidence
level
Number of
disease cases needed
Sample size
Prevalence rate 10% Prevalence rate 15% Prevalence rate 20%
0.8 0.06 0.95 715 7150 4767 3575
0.8 0.1 0.95 264 2640 1760 1320
0.9 0.06 0.95 417 4170 2780 2085
0.9 0.1 0.95 158 1580 1053 790
0.95 0.06 0.95 238 2380 1587 1190
0.95 0.1 0.95 94 940 627 470
0.96 0.06 0.95 200 2000 1333 1000
0.96 0.1 0.95 81 810 540 405
0.97 0.06 0.95 161 1610 1073 805
0.97 0.1 0.95 68 680 453 340
0.98 0.06 0.95 123 1230 820 615
0.98 0.1 0.95 55 550 367 275
0.99 0.06 0.95 87 870 580 435
0.99 0.1 0.95 44 440 293 220
CI: confidence interval.
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prevention, rather than remediation, of such a problem
will likely be less costly for the malaria control and
elimination community.
Operational considerations for G6PD testing
Although participants in the workshop’s use case scenario
session unanimously identified a point-of-care G6PD
test as the ideal product profile to support P. vivax case
management with 8-aminoquinolines, it does not ne-
cessarily follow that:
1. This product profile has a large market demand.
The workshop attendees were primarily focused on
malaria patients who are the hardest to reach rather
than on the largest number of people at risk.Table 6 Performance results for a putative qualitative diagno
described in Table 3
1
Cutoff value (U/g Hb)
Number of samples with G6PD levels less than cut-off (percentage)
Sensitivity percentage (95% CI)
Specificity percentage (95% CI)
Positive predictive value percentage (95% CI)
Negative predictive value percentage (95% CI)
CI: confidence interval; Hb: haemoglobin; U: International Unit.2. This is the best solution for all use cases. As
neonatal screening programmes improve in many
countries, a more cost-effective approach may be
to improve information management systems such
that the G6PD status of a patient is more readily
available and the need for repeat testing can
be minimized.
In Malaysia, neonatal G6PD screening is routinely per-
formed, and G6PD records accompany the patient. In a
case where a patient’s status is not known, a fluorescent
spot test is done, and primaquine is administered based
on G6PD status. In contrast, in the Philippines, neonatal
screening is supposed to be routinely done but is not
universally available, especially to remote and indigenous
populations most at risk of malaria infection.stic test modeled against the quantitative results
0% cut-off 20% cut-off 30% cut-off 60% cut-off
1.07 2.14 3.21 6.42
14 (2.8) 24 (4.8) 28 (5.6) 41 (8.2)
100 95.8 89.3 68.3
(73–100) (77–100) (71–97) (52–81)
97.1 98.9 99.4 100
(95–98) (97–100) (98–100) (99–100)
0.5 0.82 0.89 1.00
(0.31-0.69) (0.62-0.93) (0.71-0.97) (0.84-1.00)
1.00 1.00 0.99 0.97
(0.99-1.00) (0.99-1.00) (0.98-1.00) (0.95-0.98)
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ciency testing and radical cure with 8-aminoquinolines
should focus on how to ensure that G6PD status infor-
mation is available at the point of case management for
a patient presenting with P. vivax infection. This may
involve linking drug availability to availability of a point-
of-care G6PD test, to medical records, or a combination
of the two.
Another challenge with introducing and scaling up
new G6PD tests is that there are currently few guidelines
for adopting and training end users on G6PD testing and
counseling. Also, confirming or evaluating operational
effectiveness of a G6PD test in clinical settings, as op-
posed to analytical performance, will be challenging.
Additionally an external quality assurance programme
will be required. Cost analysis of different approaches to
ensuring safe delivery of 8-aminoquinolines should take
these factors into consideration, as they may significantly
influence cost-effectiveness outcomes.
Market studies segmenting where point-of-care G6PD
tests are needed in place of more complex assays will
be useful for malaria programmes in terms of resource
allocation and for suppliers in terms of understanding
the true market size. From the pricing perspective,
ideally a G6PD test would be available at the price of a
malaria RDT or less. For primaquine, given its low cost,
a significantly more expensive test will shift the burden of
the cost significantly from treatment costs to diagnostic
costs and may impact willingness to pay. Potentially
more expensive drugs may tolerate higher prices. From a
programme perspective, cost-effectiveness studies should
be designed to identify boundaries of these costs.
Conclusions
From a public health perspective, uncertainty remains
on whether G6PD testing deficiency status does not need
to be taken into account for primaquine-based radical
cure in some populations, as reflected in the current
WHO guidelines. However, from a patient management
perspective, where the individual risk/benefit ratio dictates
optimal treatment, knowing the G6PD status of the
patient is a prerequisite for prescribing an 8-aminoquino-
line-based drug.
Although many questions remain regarding G6PD
deficiency and the risk of drug-related adverse events,
this should not hinder efforts to evaluate and adopt
G6PD tests in support of radical cure. G6PD testing
represents an additional cost for malaria treatment and
unnecessary G6PD testing should be minimized. Health
systems, health management information systems, care-
seeking practices, and malaria epidemiology will determine
the best way to ensure knowledge of G6PD status for
people who have access to 8-aminoquinoline radical cure
regimens. While an approach that includes populationscreening and effective recordkeeping is attractive for
the long term, it is clear that point-of-care G6PD testing
will be required to meet immediate needs, given that the
populations most at risk of P. vivax infection are typically
those at the periphery of health care systems and the
hardest to reach. In these scenarios, significant operational
research will be required to understand how to supply
these tests, who the end users should be, how to link the
availability of the tests with that of the drugs, and how to
implement a recordkeeping system that minimizes the
need for repeat testing of individual patients.
A prerequisite to introducing G6PD testing is the
availability of high-quality G6PD tests with product
profiles that are compatible with end-use cases. Establish-
ing pragmatic and consistent criteria for evaluation of tests
should be a high priority. The development and evaluation
of new G6PD tests can benefit from the availability of
specimen panels [47]. Because factors unique to local
populations may affect the performance of G6PD tests,
another priority should be to understand the impact of
geographical and genetic diversity on the performance
of these tests.
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